Delirium Detection in Pediatric Intensive Care Unit Through a French Translation of the CAPD : a French Monocentric Observational Study (DeliReP)

December 9, 2021 updated by: Assistance Publique - Hôpitaux de Paris

Implementing Delirium Detection in Pediatric Intensive Care Unit Through a French Translation of the CAPD : a French Monocentric Observational Study

The purpose of this study is to introduce delirium detection and try to determine the prevalence of delirium in Pediatric Intensive Care Unit (PICU) using a validated tool : the Cornell Assessment of Pediatric Delirium (CAPD) for every patient twice a day.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

Delirium is a frequent affection in ICU. In adult population, its prevalence is 20-50% in non intubated patients and 60-80% in patients under invasive ventilation. It is also frequent in paediatric population, but less diagnosed, whereas it can lead to higher duration stay, higher morbidity, traumatic injuries, acute stress, memory losses and post-traumatic stress syndrome. Since 2016, international guidelines recommend to look for delirium in paediatric population in PICU. There are 3 recommended tools to diagnose this affection: psCAM-ICU (6 months-5 years old), pCAM-ICU (5 years old-18 years old) and CAPD (birth-18 years old).

None of these validated tools have been translated in French.

The principal objective is to study the practicability of twice a day detection of delirium in PICU using the CAPD.

Investigators will first used a validation process to translate the CAPD in French, based on the validation method for psychological questionnaires suggested by Vallerand.

Then they will ask the paramedics to evaluate through the CAPD every consecutive patient/12 hours, every day during their stay in PICU, except for those completely unresponsive or under curare. This systematic evaluation will take place for 2 consecutive months.

For every patient, data will be collected about their age, sexe, term of birth, mental affection status, diagnosis at entry, and daily risk of mortality score, length of stay, ventilation, pain evaluation and treatment, withdrawal evaluation, surroundings, use of hypnotic treatment, steroids, opioids and ketamine.

The secondary aims are to determine the prevalence of delirium with the data collected, to ask whether or not the French version of CAPD has been easily and correctly used, can help to diagnose delirium, and whether investigators can find some associated parameters to delirium.

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75015
        • Necker Enfants malades hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients aged 0 to 18 years hospitalized in PICU at Necker Children's Hospital

Description

Inclusion Criteria:

  • Being hospitalized in PICU during the inclusion period
  • Age 0 to 18 years old

Exclusion Criteria:

  • Patient with a state of sedation that does not allow the assessment of a change in the state of consciousness or cognitive functioning (equivalent score Richmond Agitation-Sedation Scale RASS <-3 or COMFORT B <11)
  • Patient or Parental opposition to the observational study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of delirium in the PICU population
Time Frame: 2 months
Number of CAPD evaluated > 9 / total number of CAPD evaluated
2 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Applicability of the CAPD by the paramedics
Time Frame: Before inclusion period

5 questions :

  1. Whether or not they have already heard about delirium
  2. Whether or not they know the symptoms of delirium in children and adolescents
  3. Whether or not they have already been confronted to a state of delirium in the Pediatric Intensive Care Unit
  4. Whether of not they think it would be useful to have a specific scale to diagnose delirium in the Pediatric Intensive Care Unit
  5. Whether or not they think it would be feasible to use such a scale regularly in the Pediatric Intensive Care Unit The proposed answers will be Yes, No or I don't know for each question The analysis will be qualitative and quantitative.
Before inclusion period
Applicability of the CAPD by the paramedics after the 2 months period
Time Frame: 2 months

The same 5 questions of the pre-test, 5 new closed-ended questions and 3 open-ended questions :

  1. Whether or not they had difficulties evaluating patients with the CAPD
  2. How they evaluate the duration of the evaluation by the CAPD
  3. Whether or not they evaluated the patients with a colleague
  4. Whether or not they think that the assessment of delirium by the CAPD is relevant among PICU patients
  5. Whether or not they think that a long-term evaluation of delirium by the CAPD is feasible in this PICU unit

1- If difficulties of evaluating patients with the CAPD : quote the difficulties 2- In which categories of patients do they think that the CAPD in not adapted 3- Comment or suggestions to improve the use of the scale

2 months
Use of the CAPD by the paramedics
Time Frame: 2 months
% of CAPD completed during the 2 months period
2 months
Age
Time Frame: 2 months
Potential associated factors to delirium
2 months
Sex
Time Frame: 2 months
Potential associated factors to delirium
2 months
Term of birth
Time Frame: 2 months
Potential associated factors to delirium
2 months
Prior neurological impairment
Time Frame: 2 months
Potential associated factors to delirium
2 months
Diagnosis (motivating hospitalization in intensive care)
Time Frame: 2 months
Potential associated factors to delirium
2 months
Severity score on arrival (PIM 3)
Time Frame: 2 months
Potential associated factors to delirium. Pediatric Index of Mortality (PIM) 3 is a published and open acces program whith 10 variables about the patients (7 binary variables and 3 quantitative ones), that predicts the death probability of the patient. One evaluation per patient at the admission in the PICU unit.
2 months
Daily severity score (PELOD 2)
Time Frame: 2 months
Potential associated factors to delirium. PELOD 2 (PEdiatric Logistic Organ Dysfunction) is a published and open acces program that includes ten variables corresponding to five organ dysfunctions. It predicts a daily percentage of mortality. One evaluation per day per patient during the PICU unit stay.
2 months
Duration of hospitalization
Time Frame: 2 months
Potential associated factors to delirium
2 months
Death or survival of the patient
Time Frame: 2 months
Potential associated factors to delirium
2 months
Mechanical ventilation, non invasive ventilation or spontaneous ventilation
Time Frame: 2 months
Potential associated factors to delirium
2 months
Mechanical ventilation time
Time Frame: 2 months
Potential associated factors to delirium
2 months
Presence of parents
Time Frame: 2 months
Potential associated factors to delirium
2 months
Presence of pain
Time Frame: 2 months

Potential associated factors to delirium.

Pain was evaluated through the appropriate scale amongst :

  • Comfort B (pediatric behavioural scale, ventilated, sedated and/or comatose patient): seven items scored 1 to 5, a total score greater than or equal to 17/35 indicating a state of pain,
  • or EVENDOL (behavioural scale for conscious patients between birth and 6 years old): five items scored 0 to 3, a total score greater than or equal to 3/15 indicating a state of pain,
  • or FLACC (Face Leg Activity Cry Consolability) (pediatric behavioural scale, usable in patients with cognitive impairment): five items scored 0 to 2, a total score greater than or equal to 3/10 indicating a state of pain,

Patients able to assess pain felt :

  • Numerical Scale (for patients over 10 years old) a score greater than or equal to 3/10 indicating a state of pain,
  • or Visual Analogue Scale (for patients between 6 and 10 years old), a score greater than or equal to 3/10 indicating a state of pain.
2 months
withdrawal or not
Time Frame: 2 months
Potential associated factors to delirium. Withdrawal was evaluated through the scale WAT-1 (Wthdrawal Assessing tool version 1): ten items scored 0 or 1, and 1 item scored 0 to 2, a total score greater than or equal to 3/12 indicating a state of withdrawal.
2 months
Use of benzodiazepines, ketamine, corticosteroids or opioids
Time Frame: 2 months
Potential associated factors to delirium
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Laure De Saint Blanquat, MD, PhD, Assistance Publique - Hôpitaux de Paris

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 6, 2018

Primary Completion (Actual)

December 6, 2018

Study Completion (Actual)

December 6, 2018

Study Registration Dates

First Submitted

September 7, 2018

First Submitted That Met QC Criteria

July 5, 2021

First Posted (Actual)

July 8, 2021

Study Record Updates

Last Update Posted (Actual)

December 10, 2021

Last Update Submitted That Met QC Criteria

December 9, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

Clinical Trials on CAPD

3
Subscribe